

## AXIRON® NET SALES, QUARTER TO 30 SEPTEMBER 2017

---

Acrux (ASX: ACR) today confirmed that Eli Lilly and Company reported global Axiron® net sales of US\$7.9 million in its financial results for the quarter ending 30 September 2017. As previously announced, termination of the Axiron® license in the United States became effective on 5<sup>th</sup> September 2017 and outside the US on 4<sup>th</sup> December 2017.

### **For further information, contact**

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

### **About Acrux**

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit [www.acrux.com.au](http://www.acrux.com.au)

